Victoria Johnson

New research highlights the importance of lifestyle changes to combat knee osteoarthritis, revealing obesity and knee injuries as key risk factors.

COVID-19 vaccination had a particularly protective effect in males and those with anxiety or depression.

Adolescent gout rates are rising globally, highlighting the need for early intervention and lifestyle changes to mitigate health risks.

A new meta-analysis reveals aquatic exercise and resistance training as the top therapeutic exercises for reducing fibromyalgia pain in women.

SELARSDI gains FDA interchangeability with Stelara, enhancing access to affordable treatments for psoriatic arthritis, psoriasis, Crohn's, and ulcerative colitis.

This FDA News Month in Review provides a round-up of regulatory decisions from April 2025.

A new study utilizing machine learning reveals how physical activity reduces gout risk in people with hyperuricemia.

New findings highlight the link between fibromyalgia syndrome and increased rates of astigmatism, dry eye disease, and meibomian gland dysfunction.

A recent study reveals a significant prevalence of gout in end-stage renal disease patients, highlighting the complex relationship between kidney function and uric acid levels.

Upadacitinib joins tocilizumab as the second therapy to be approved for treating GCA.

Pegloticase treatment significantly improves serum urate levels and quality of life in kidney transplant recipients with gout, showing promising clinical benefits.

Recent research highlights low certainty in sleep interventions for fibromyalgia, yet exercise shows promise in improving sleep quality.

New findings refine neuropathic pain treatment guidelines, emphasizing effective medications and the importance of personalized care for improved patient outcomes.

Ten percent of effector genes identified express proteins targeted by approved drugs across disease fields.

Febuxostat was associated with a nearly 3-fold higher risk of mild to moderate perturbation of liver function than benzbromarone.

Participants experienced significant improvements in pain, sleep, and physical function.

Significant associations were seen in males, Mexican Americans, married individuals, those with insufficient physical activity, and those with diabetes.

People with ME/CFS also have a high comorbidity rate of fibromyalgia, which has also been seen to improve with aquatic exercise.

More studies are needed to assess whether creatinine or and hyperuricemia may be prognostic factors for these patients.

After a primary analysis revealed no significant differences in pain, exploratory outcomes in the FINAL trial also revealed no significant findings.

Our Q1 2025 recap for rheumatology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in rheumatology care.

The rheumatology month in review emphasizes new research in gout, fibromyalgia, and psoriatic arthritis.

The rheumatology month in review emphasizes new research in gout, fibromyalgia, and psoriatic arthritis.

This FDA News Month in Review provides a round-up of regulatory decisions from March 2025.

By 3 months, nearly all patients confirmed exposed to 30 or 60 mg SAP-001 reached serum uric acid levels below 6mg/dL.

Small but significant decreases were also seen in depression and anxiety scores in people with and without psoriatic arthritis.

Hazard ratios of MACE were similar between patients treated with ustekinumab, adalimumab, etanercept, and secukinumab.

Other risk factors in the population included PZA or ETB use, hypertension, heart failure, and chronic kidney disease.

The two treatments appeared to be similar in cost-effectiveness and efficacy in a small analysis.